What is US 9,388,188 B2 for (sitagliptin)?
US 9,388,188 B2 is a patent that concerns sitagliptin. The exact claims and scope are not provided in the information available here, so I can’t accurately state what the invention covers (for example, whether it is about specific formulations, polymorphs, methods of treatment, or manufacturing/process details).
If you paste the patent title/abstract (or the claims you care about), I can summarize what US 9,388,188 B2 covers in plain English and identify the parts most likely to matter for products or generic entry.
How can I find the exact claims and details for US 9,388,188 B2?
To interpret a sitagliptin patent like US 9,388,188 B2, the most useful parts are:
- The patent “Title” and “Abstract” (what problem it solves)
- The first independent claim(s) (what is protected)
- The dependent claims (what specific embodiments are also protected)
- The “Field of the Invention” and “Summary” sections (context for claim scope)
If you share the abstract/title or a link to the patent text you’re using, I can extract the relevant protections and translate them.
When does US 9,388,188 B2 expire (and is it relevant to generic sitagliptin entry)?
Patent expiration depends on factors such as:
- The filing date (utility patents generally expire based on time from earliest effective non-provisional filing date, subject to adjustments)
- Any term adjustments granted by the USPTO
- Whether there are terminal disclaimers or other maintenance/validity issues
I don’t have the filing date/priority information or any USPTO term-adjustment data for US 9,388,188 B2 in what you provided, so I can’t compute the expiration date.
Has US 9,388,188 B2 been litigated or challenged?
Whether US 9,388,188 B2 has been challenged (e.g., by an ANDA party via IPR/CBM or through district court litigation) depends on the specific docket history and filings, which isn’t included here. If you share the case caption(s) or a source (USPTO, court PACER summary, RECAP, or a litigation database link), I can connect those documents to the patent and explain what was argued.
What matters most if you’re trying to assess “design-around” risk for sitagliptin?
For sitagliptin patents, the key practical question is usually whether a generic or alternative product practices the same protected features as the independent claim(s). That turns on:
- Formulation ingredients and ratios (if it’s a formulation patent)
- Particle size, polymorph/solid-state form, or crystallinity (if it’s a solid-state/form patent)
- Dosing regimen and patient selection criteria (if it’s a method-of-use patent)
- Manufacturing steps (if it’s a process patent)
Without the claim text, I can’t tell which of these is the real risk driver for US 9,388,188 B2.
What I need from you to answer precisely
Reply with any one of the following, and I’ll produce a focused, accurate explanation of US 9,388,188 B2:
1) The patent title + abstract, or
2) A screenshot/paste of the independent claims, or
3) A link to the patent page you’re using (USPTO or Google Patents)
Sources: none provided in your message.